Madrigal Pharmaceuticals to Speak at Investor Conference
On October 2, 2024, Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced its participation in an exciting opportunity at the H.C. Wainwright 8th Annual MASH Virtual Investor Conference. The company will be part of a live fireside chat scheduled for 2:00 PM ET on October 7, 2024.
Details of the Event
The fireside chat promises to be insightful, addressing key developments in the company’s ongoing efforts to innovate therapeutics targeting liver diseases. Investors and interested parties can access the live webcast for free, making it more convenient for those eager to stay updated on the company’s progress.
Accessing the Broadcast
Participants can join the conversation online through Madrigal's website under the Investor Relations Events section. Those unable to attend the live session will have the chance to view a replay shortly after the event concludes, ensuring that all interested parties can catch up on important insights shared.
Understanding Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. is at the forefront of developing novel therapeutics specifically for nonalcoholic steatohepatitis (NASH), a complex liver disease with significant unmet medical needs. The company’s lead product candidate, Rezdiffra (resmetirom), is designed to be taken once daily and works as a THR-? agonist, targeting critical measures underlying the progression of NASH.
Commitment to Innovation
With a robust pipeline and a commitment to scientific discovery, Madrigal continues to push the boundaries in the fight against liver diseases. The company’s dedication to research and development is evident through its focus on delivering effective treatment options that address the intricacies of NASH.
Contacting Madrigal Pharmaceuticals
For investors and media inquiries, Madrigal has established dedicated contact points. Tina Ventura represents investor relations while media queries can be directed to Christopher Frates. Both contacts provide valuable avenues for stakeholders eager to engage with the company and learn more about their innovative efforts.
Staying Informed
To stay informed about Madrigal’s upcoming events, potential investors and other stakeholders are encouraged to regularly visit their Investor Relations webpage. This resource will provide updates on events, webcasts, financial reports, and other critical company communications.
Frequently Asked Questions
What is the purpose of the fireside chat at the conference?
The fireside chat aims to share insights into Madrigal Pharmaceuticals' strategies and developments in innovative liver disease therapeutics.
How can I access the webcast of the fireside chat?
The webcast can be accessed on Madrigal's Investor Relations page, where it will be streamed live and made available for replay later.
What is Rezdiffra and its significance?
Rezdiffra (resmetirom) is a biopharmaceutical product designed to treat NASH, addressing an urgent medical need in liver health.
Who can I contact for more information on investor relations?
Tina Ventura is the appropriate contact for investor relations inquiries at Madrigal Pharmaceuticals.
Is there a way to follow updates from Madrigal Pharmaceuticals?
Yes, you can follow updates by visiting Madrigal’s website and subscribing to their news alerts for the latest information.
